Raymond James & Associates Trims Stock Position in G1 Therapeutics, Inc. (NASDAQ:GTHX)

Raymond James & Associates lowered its stake in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) by 38.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 565,555 shares of the company's stock after selling 360,221 shares during the period. Raymond James & Associates owned about 1.09% of G1 Therapeutics worth $1,725,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Creative Financial Designs Inc. ADV boosted its holdings in G1 Therapeutics by 98.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company's stock worth $108,000 after purchasing an additional 17,475 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in G1 Therapeutics by 68.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 204,200 shares of the company's stock worth $294,000 after purchasing an additional 82,879 shares in the last quarter. Acadian Asset Management LLC bought a new stake in G1 Therapeutics in the third quarter worth $189,000. Algert Global LLC bought a new stake in G1 Therapeutics during the third quarter valued at about $98,000. Finally, Curi Wealth Management LLC boosted its holdings in G1 Therapeutics by 17.8% during the third quarter. Curi Wealth Management LLC now owns 70,742 shares of the company's stock valued at $102,000 after acquiring an additional 10,700 shares during the period. Institutional investors and hedge funds own 24.21% of the company's stock.

Wall Street Analysts Forecast Growth

GTHX has been the subject of a number of recent analyst reports. Needham & Company LLC restated a "buy" rating and set a $12.00 price target on shares of G1 Therapeutics in a report on Friday, April 12th. Wedbush restated an "outperform" rating and set a $5.00 price target (up from $4.00) on shares of G1 Therapeutics in a report on Wednesday, February 28th.

G1 Therapeutics Price Performance

NASDAQ:GTHX traded down $0.11 during mid-day trading on Thursday, hitting $4.17. The company's stock had a trading volume of 687,514 shares, compared to its average volume of 1,344,192. G1 Therapeutics, Inc. has a fifty-two week low of $1.08 and a fifty-two week high of $5.00. The company has a current ratio of 3.87, a quick ratio of 3.45 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $217.80 million, a price-to-earnings ratio of -4.39 and a beta of 1.73. The stock has a fifty day moving average of $3.63 and a 200-day moving average of $2.86.

G1 Therapeutics (NASDAQ:GTHX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.06. G1 Therapeutics had a negative net margin of 58.13% and a negative return on equity of 106.04%. The firm had revenue of $14.87 million during the quarter, compared to analyst estimates of $12.83 million. During the same quarter in the prior year, the business posted ($0.73) earnings per share. As a group, equities analysts forecast that G1 Therapeutics, Inc. will post -0.64 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Rajesh Malik sold 28,600 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $4.62, for a total value of $132,132.00. Following the completion of the transaction, the insider now owns 169,938 shares of the company's stock, valued at $785,113.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 8.23% of the company's stock.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.